Biomarin Pharmaceutical (BMRN) Operating Expenses (2009 - 2026)

Over the trailing twelve months to Jun 30, 2026, Biomarin Pharmaceutical reported Operating Expenses of $3.26 billion, up 42.4% year-over-year; for FY2025, it was $2.81 billion, up 18.7% from FY2024.

• Operating Expenses has increased in each of the last eight years, with a five-year compound annual growth rate of 8.1% (FY2020 to FY2025).
• Going back by year, Operating Expenses was $2.37 billion in FY2024 (+6.1%), $2.23 billion in FY2023 (+15.4%), $1.94 billion in FY2022 (+0.3%) and $1.93 billion in FY2021 (+1.3%).
• The five-year range for quarterly Operating Expenses is $382.03 million (Q1 2022) to $919.18 million (Q4 2025).
• Year-over-year, Operating Expenses has increased for four consecutive quarters, with growth averaging 20.6% over the last eight quarters.
• The fastest year-over-year change in Operating Expenses over five years came in Q2 2026 (growth of 60.2%), and the weakest in Q1 2022 (a decline of 17.1%).
• Business Quant data shows BMRN's Operating Expenses at $636.57 million (Q1 2026), $919.18 million (Q4 2025) and $822.83 million (Q3 2025) in the three quarters before Q2 2026.